~~<i id='DC95AA6596'><strike id='DC95AA6596'><tt id='DC95AA6596'><pre id='DC95AA6596'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

explore

author：comprehensive 2025-10-02 00:42:05 - browse：113

An advisory panel to the Food and Drug Administration delivered a split decision on a surgical system used in a controversial blood pressure treatment called renal denervation.

The panel, whose advice the FDA typically follows, voted that the system developed by ReCor Medical was safe and effective. It voted that the benefits of a system developed by Medtronic, however, did not outweigh the risks.

“While this is a very safe procedure, the efficacy was mild at best,” Keith Allen, director of surgical research at St. Luke’s Hospital of Kansas City, said regarding Medtronic’s device.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Biotech companies concerned about China biosecurity crackdown

explore

knowledge

hotspot

focus

Imageofoneofthechimerichuman-monkeyembryos.SalkInstituteforBiologicalStudiesAteamofscientistsfromthe

WSS

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Montana youths win climate lawsuit against state for promoting fossil fuels

BMS, looking to build heart drug business, turns to AI for diagnosis

Indictment alleges Trump's ex

Be careful with at

FogPharma raises $145 million in rare Series E round

focus

explore

explore

As demand for Covid shots wanes, Moderna seeks its next success

What to know about the judge who will handle the Trump case

Psychedelics group wrestles with new pharma identity

In search for therapies for solid tumors, companies turn to claudin

Affirmative action in medical school literally saved lives

Kenai launches with $82 million for Parkinson’s stem cell therapy

What does generative AI mean for health care? We asked experts

ALS groups 'won't be played again' by the FDA, drug sponsors

United colonoscopy coverage change 'may cost lives,' doctors say

Why getting cancer drugs just got harder for rural patients

knowledge

BMS, looking to build heart drug business, turns to AI for diagnosis

How to address the problem of discarded donor organs

Judge sides with young activists in first

Patients, digital health players weigh in on FTC's data privacy plan

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

An inside look at PIPEs, biotech's buzzy new financing tool

hotspot

focus

focus

focus